We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$5.41M
Cap. Flow %
-0.08%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.81%
2 Financials 1.53%
3 Miscellaneous 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
151
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,605,713
Closed -$45.3M
RARX
152
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-376,894
Closed -$8.91M
BOLD
153
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-1,588,069
Closed -$44.6M
ONCE
154
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-244,900
Closed -$23.8M
AVDR
155
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-4,240,128
Closed -$96.3M
ALDR
156
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-350,000
Closed -$6.6M
3 4 5 6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.